Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
REAL-WORLD EFFECTIVENESS OF RSV VACCINES AMONG ADULTS USING TARGET TRIAL EMULATION IN EPIC COSMOS
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework
調査の概要
状態
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10001
- Pfizer
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will include non-pregnant adults aged ≥18 years and ≥ 60 years in the United States with care observed in Epic Cosmos, contributing healthcare systems on or after August 2023. Individuals will be required to have sufficient healthcare engagement to ensure adequate data capture and observability within the database. Within this population, vaccinated individuals will be identified by documented administration of an RSV vaccine in structured EHR data.
説明
Inclusion:
Vaccinated Cohort
Patients must meet all the following inclusion criteria to be eligible for inclusion in the study:
- Adults meet the age criteria at the index date.
- Non-pregnant at the index date.
- Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
- Have a documented administration of ABRYSVO® (or AREXVY®,mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.
The index date for vaccinated individuals will be defined as the date of RSV vaccination.
Unvaccinated Cohort
Patients must meet all the following inclusion criteria to be eligible for inclusion in the study (in unvaccinated cohort):
- Adults meet the age criteria at the index date.
- Non-pregnant at the index date.
- Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
- Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.
The index date for unvaccinated individuals will be defined as the start date of each sequential trial ('e.g.', 1st date of each month) in which they met eligibility criteria
Exclusion:
Exclusion Criteria Vaccinated Cohort
Patients meeting any of the following criteria will not be included in the study:
- Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).
- Non-US residents. Unvaccinated Cohort
Patients meeting any of the following criteria will not be included in the study (in unvaccinated cohort):
- Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.
- Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:RETROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Vaccinated group
Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna) |
|
Unvaccinated comparator group:
Individuals not yet vaccinated at cohort entry, but otherwise eligible |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
時間枠:up to 3 years
|
up to 3 years
|
|
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
時間枠:up to 3 years
|
up to 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of RSV-related outcomes
時間枠:up to 3 years
|
ARI/LRTD non-inpatient encounter, ARI/LRTD severe outcome, ARI/LRTD critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, Immunocompromised status and pneumonia with different care settings. |
up to 3 years
|
|
Incidence of All-cause outcomes
時間枠:up to 3 years
|
all-cause ARI/LRTD encounter with different care settings, severe outcome, critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, pneumonia with different care settings, Immunocompromised status and dementia (new onset). |
up to 3 years
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- C3671094
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。